Oculis Announces Positive Data from Two Proof-of-Concept Phase 2 Trials with OCS-02, a Novel Topical TNF alpha Antagonist, in Dry Eye Disease and Acute Anterior Uveitis, Presented at ARVO 2021

11 May, 2021

Oculis Announces an Oversubscribed US$57 million Series C Financing

04 May, 2021

Oculis to Present Recent Progress in its Portfolio at Upcoming Investor Conferences

24 November, 2020

Oculis appoints David Jacobs, M.D. as Chief Development Officer

22 October, 2020

Oculis announces presentation of OCS-01 Phase 2 DME study at EURETINA 2020

05 October, 2020

Oculis to present recent milestones at key biotech and ophthalmology conferences

22 September, 2020

Oculis recognized as one of the Top 100 Swiss Startups and ranked in Top 10 Biotech

10 September, 2020

Oculis establishes presence in U.S. and appoints Sylvia Cheung as Chief Financial Officer

01 September, 2020

Oculis to Present at the Upcoming 2020 Summer Private Company Showcase

10 August, 2020

Oculis to Present at the LifeSci Partners Private Company Virtual Summer Symposium

30 July, 2020

Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01

27 July, 2020

Oculis to Present at the Upcoming Virtual European Biotech Investor Day 2020

23 June, 2020

Oculis Reports Positive Top-line Data from SKYGGN (Phase 2) Trial with OCS-01

18 May, 2020

Oculis Announces Upcoming Presentation of SKYGGN Phase 2 Data at ASCRS

07 May, 2020

Oculis Appoints Dr. Frédéric Pilotaz as VP of Technology & Pharmaceutical Sciences

21 April, 2020

Oculis Appoints Marcia de Souza Lima, M.D., as Chief Medical Officer

03 March, 2020

Phase 2 Study Results of OCS-01: A Potential Topical Therapeutic for DME

10 February, 2020

Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in DME

22 January, 2020

Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Trial

07 October, 2019

Oculis Announces Appointment of Leading Specialists to Scientific Advisory Board

17 September, 2019

Why a pharma investor quit his day job to follow a vision (Guest interview)

16 May, 2019

Oculis Expands Portfolio with a Novel Phase II-stage Anti-TNF alpha Antibody Fragment

04 January, 2019

Oculis Raises CHF15.5 million in an Extension of its Series B Financing Round

04 January, 2019

Oculis Strengthens its Global Clinical and Business Development Capabilities

20 November, 2018

Oculis appoints Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board

25 September, 2018

Oculis elects Anthony Rosenberg David A. Weber to its Board of Directors

19 September, 2018

Oculis Raises CHF20 million in a Series B Financing Round to Advance Treatments

01 January, 2018